<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147780</url>
  </required_header>
  <id_info>
    <org_study_id>2019-04647</org_study_id>
    <nct_id>NCT04147780</nct_id>
  </id_info>
  <brief_title>Sentinel Node Extended in Squamous Cell Vulvar Cancer</brief_title>
  <acronym>SNEX</acronym>
  <official_title>Can the Investigators Extend the Indication for Sentinel Node Biopsy in Vulvar Cancer? A Nationwide Feasibility Study From Sweden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diana Zach</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the feasibility of sentinel node biopsy in patients
      with squamous cell vulvar cancer, currently not regarded suitable for the sentinel node
      technique, i.e. patients with tumors ≥4cm, multifocal tumors or locally recurrent disease. A
      positive result of this pilot study might constitute the basis for a future full-scale
      multinational trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      This study is primarily a pilot and feasibility trial, aiming to evaluate if sentinel node
      biopsy has a satisfactory detection rate and negative predictive value in certain groups of
      vulvar cancer patients.

      OUTLINE:

      The study is planned as a prospective, multi-center cohort study in Sweden. Since 2017, the
      treatment of vulvar cancer patients has been accredited to four tertiary referral university
      hospitals in Sweden; the Sahlgrenska University hospital in Gothenburg, the Linköping
      University hospital, the Skåne University hospital in Lund and the Karolinska University
      hospital in Stockholm.

      Eligible patients will undergo a sentinel node biopsy additionally to their radical
      inguinofemoral lymphadenectomy and detection rate and negative predictive value for the
      sentinel procedure will be calculated. The study will consist of four patient groups:
      Patients with squamous cell vulvar cancer and:

        1. primary tumors ≥4cm

        2. primary multifocal tumors

        3. local recurrence, earlier no treatment of the groins or only sentinel node biopsy

        4. local recurrence, earlier treatment of the groins with radiotherapy / inguinofemoral
           lymphadenectomy

      It is estimated to include 20-30 patients in each study group during a time frame of about 24
      months.

      RESULTS:

      Results are to be expected in the end of 2021.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate and negative predictive value for sentinel node biopsy</measure>
    <time_frame>2019-2021</time_frame>
    <description>Calculated for each group separately. Per groin and per patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of retrieved sentinel lymph nodes</measure>
    <time_frame>2019-2021</time_frame>
    <description>Per groin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of micrometastases and isolated tumor cells, diagnosed by ultra-staging in relation to routine-histopathological examination</measure>
    <time_frame>2019-2021</time_frame>
    <description>Per groin and per patient</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Vulva Cancer</condition>
  <condition>Sentinel Lymph Node</condition>
  <arm_group>
    <arm_group_label>Primary vulvar cancer, tumor ≥ 4cm</arm_group_label>
    <description>Patients with primary squamous cell vulvar cancer, unifocal tumor ≥ 4cm:
Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary vulvar cancer, multifocal tumor</arm_group_label>
    <description>Patients with primary squamous cell vulvar cancer, multifocal tumor:
Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Local recurrence after vulvar cancer, no earlier treatment</arm_group_label>
    <description>Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier without treatment of the groins or solely sentinel node biopsy:
Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Local recurrence after vulvar cancer, earlier treatment</arm_group_label>
    <description>Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier treatment of the groins by lymphadenectomy and / or (chemo-)radiation:
Sentinel node biopsy if detectable, otherwise no groin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel node biopsy</intervention_name>
    <description>Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.</description>
    <arm_group_label>Local recurrence after vulvar cancer, earlier treatment</arm_group_label>
    <arm_group_label>Local recurrence after vulvar cancer, no earlier treatment</arm_group_label>
    <arm_group_label>Primary vulvar cancer, multifocal tumor</arm_group_label>
    <arm_group_label>Primary vulvar cancer, tumor ≥ 4cm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with primary squamous vulvar cancer with tumors ≥ 4cm or multifocal tumors,
        and all patients with a local recurrence after primary squamous vulvar cancer in Sweden,
        diagnosed during the recruitment period
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with squamous cell vulvar cancer and

               1. primary tumors ≥ 4cm

               2. multifocal primary tumors

               3. local recurrence, earlier no treatment of the groins or only sentinel node biopsy

               4. local recurrence, earlier treatment of the groins with radiotherapy /
                  inguinofemoral lymphadenectomy

          -  ≥ 18 years of age

          -  Considered clinically appropriate for surgery

          -  Informed consent

        Exclusion Criteria:

          -  Eastern Cooperative Oncology Group performance status &gt; 2

          -  Disability to read or write in Swedish

          -  Dementia / severe psychiatric illness leading to disability to understand the study /
             study information

          -  Signs of inguinal lymph node or distant metastases

          -  Ongoing pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Zach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Zach, MD</last_name>
    <phone>+46851775922</phone>
    <email>diana.zach@sll.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Lan</state>
        <zip>17776</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Zach, MD</last_name>
      <phone>+46851775922</phone>
      <email>diana.zach@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katja Stenstrom Bohlin, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkopings University Hospital</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Preben Kjoelhede, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skanes University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Moberg, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Diana Zach</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Data excess requests will be reviewed by an external independent review panel. Requestors will be required to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

